{
    "Trade/Device Name(s)": [
        "DASH SARS-CoV-2 & Flu A/B Test",
        "DASH\u00ae SARS-CoV-2 & Flu A/B Test"
    ],
    "Submitter Information": "Nuclein, LLC",
    "510(k) Number": "K241652",
    "Predicate Device Reference 510(k) Number(s)": [
        "K230719"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QOF",
        "NSU"
    ],
    "Summary Letter Date": "September 25, 2024",
    "Summary Letter Received Date": "September 25, 2024",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-Cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA",
        "Influenza A RNA",
        "Influenza B RNA"
    ],
    "Specimen Type(s)": [
        "Anterior nasal swab"
    ],
    "Specimen Container(s)": [
        "DASH SARS-CoV-2 & Flu A/B Test cartridge (sample chamber)",
        "Anterior nares nasal swab (30-mm breakpoint)"
    ],
    "Instrument(s)/Platform(s)": [
        "DASH Rapid PCR Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Reverse transcription polymerase chain reaction (RT-PCR)",
        "Sequence specific capture",
        "PCR amplification",
        "Fluorescence detection"
    ],
    "Methodologies": [
        "RT-PCR",
        "Sequence-specific capture and amplification"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test",
        "Cartridge",
        "Instrument",
        "Control",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for DASH SARS-CoV-2 & Flu A/B Test, a rapid RT-PCR assay using the DASH Rapid PCR Instrument for qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B in anterior nasal swabs",
    "Indications for Use Summary": "Intended for rapid in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B RNA in anterior nasal swab specimens from symptomatic patients to aid differential diagnosis in conjunction with other clinical, epidemiologic, and laboratory findings",
    "fda_folder": "Microbiology"
}